Results 51 to 60 of about 7,440,138 (398)
Application of pharmacogenomics and bioinformatics to exemplify the utility of human ex vivo organoculture models in the field of precision medicine [PDF]
, 2019 Here we describe a collaboration between industry, the National Health Service (NHS) and academia that sought to demonstrate how early understanding of both pharmacology and genomics can improve strategies for the development of precision medicines ...
A Cilli +42 more
core +2 more sources
Molecules, 2020 During 2019, the US Food and Drug Administration (FDA) approved 48 new drugs (38 New Chemical Entities and 10 Biologics). Although this figure is slightly lower than that registered in 2018 (59 divided between 42 New Chemical Entities and 17 Biologics ...
B. G. de la Torre, F. Albericio
semanticscholar +1 more source
Accelerating antiviral drug discovery: lessons from COVID-19
Nature reviews. Drug discovery, 2023 During the coronavirus disease 2019 (COVID-19) pandemic, a wave of rapid and collaborative drug discovery efforts took place in academia and industry, culminating in several therapeutics being discovered, approved and deployed in a 2-year time frame ...
Annette von Delft +7 more
semanticscholar +1 more source
Prevalence of tablet splitting in a Brazilian tertiary care hospital
Pharmacy Practice, 2020 Background: Although a highly common practice in hospital care, tablet splitting can cause dose variation and reduce drug stability, both of which impair drug therapy. Objective: To determine the overall prevalence of tablet splitting in hospital care
Vivianne V. Melo +6 more
doaj +1 more source
Regulating the drugs industry transparently [PDF]
BMJ, 2005 Over the past 10-15 years, drug regulatory authorities in the United Kingdom and elsewhere have streamlined and accelerated the review of new drugs in response to claims by the pharmaceutical industry that over-regulation was stifling innovation.1,2 Despite these policies, the number of new molecular entities—a standard measure of innovation in the ...
openaire +4 more sources
Phenotype standardization for drug-induced kidney disease. [PDF]
, 2015 Drug-induced kidney disease is a frequent cause of renal dysfunction; however, there are no standards to identify and characterize the spectrum of these disorders.
Awdishu, Linda +8 more
core +2 more sources
Synthesis and Antitumor Activity of (3-Hydroxyacrylato-O,O′) Diammineplatinum(II)
Pharmaceutical Fronts, 2021 As an indispensable part of cancer chemotherapy, platinum drugs still play an important role in cancer treatment. In this study, two platinum(II) complexes with Michael acceptor 3-hydroxyacrylic acid as the leaving group were synthesized from cis ...
Yong-Zhi Shu +6 more
doaj +1 more source
Automation potential of a new, rapid, microscopy based method for screening drug-polymer solubility [PDF]
, 2020 For the pharmaceutical industry, the preformulation screening of the compatibility of drug and polymeric excipients can often be time-consuming because of the use of trial-and-error approaches.
Alhijjaj, Muqdad +4 more
core +1 more source
Responsibilities of the Marketing Authorisation Holders in Respect of GMP Compliance (Review)
Разработка и регистрация лекарственных средств, 2020 Introduction. The article is focused on differences in quality assurance-related obligations and responsibilities between Marketing Authorisation Holders (MAHs) and manufacturing authorisation holder (manufacturers) in pharmaceutical industry. In case of
A. P. Meshkovskiy +7 more
doaj +1 more source
Drugs for neglected diseases: a failure of the market and a public health failure? [PDF]
, 2001 Infectious diseases cause the suffering of hundreds of millions of people, especially in tropical and subtropical areas. Effective, affordable and easy-to-use medicines to fight these diseases are nearly absent.
Foster, S +6 more
core +2 more sources